Microparticle-associated tissue factor is recycled by endothelial cells resulting in enhanced surface tissue factor activity

Summary

In this study the uptake of tissue factor (TF)-positive microparticles by endothelial cells and the recycling of the TF component were examined. Human dermal blood endothelial cells (HDBEC) were incubated with microparticles derived from cancer cell lines for up to 6 hours. Measurement of HDBEC cell surface TF antigen revealed two distinct peaks at 30 and 180–240 minutes post-incubation with TF-positive, but not TF-deficient microparticles. However, only the second peak was concurrent with high TF activity as determined by a chromogenic thrombin-generation assay. Annexin V-labelling of HDBEC showed phosphatidylserine exposure following 90 minutes incubation with microparticles, which explains the high TF activity associated with the second antigen peak. Analysis of TF mRNA levels revealed no de novo expression of TF mRNA in response to microparticles, and pre-incubation of cells with cycloheximide did not prevent the appearance of TF. However, blocking endocytosis with a dynamin inhibitor prolonged the disappearance and prevented the reappearance of TF antigen on the cell surface. Incubation of HDBEC with microparticles containing TF-GFP revealed the early co-localisation of TF with Rab4 and Rab5, followed by co-localisation with the late endosomal/trans-Golgi network marker Rab9, and the recycling endosome marker Rab11. siRNAmediated suppression of Rab11 reduced the reappearance of TF on the cell surface. These data suggest a mechanism by which TF-containing microparticles are internalised by endothelial cells and the TF moiety recycled to the cell surface. Together with the exposure of phosphatidylserine, this is capable of inducing a substantial increase in the procoagulant potential of the surface of endothelial cells.

Keywords

Tissue factor - microparticles - endothelial cells - procoagulant activity - recycling - endosome

^* M.E.W.C. and P-M.M. contributed equally to this study.

• References

• 1 Levine MN. et al. From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. J Thromb Haemost 2003; 1: 1456-1463.
• 2 Callander NS. et al. Immunohistochemical identification of tissue factor in solid tumors. Cancer 1992; 70: 1194-1201.
• 3 Shoji M. et al. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998; 152: 399-411.
• 4 Kakkar AK. et al. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995; 82: 1101-1104.
• 5 Seto S. et al. Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer 2000; 88: 295-301.
• 6 Nitori N. et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res 2005; 11: 2531-2539.
• 7 Yu JL, Rak JW. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2004; 2: 2065-2067.
• 8 Zwicker JI. et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15: 6830-6840.
• 9 Tesselaar ME. et al. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J Thromb Haemost 2007; 5: 520-527.
• 10 Zwicker JI. et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15: 6830-6840.
• 11 Vrana JA. et al. Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family. Cancer Res 1996; 56: 5063-5070.
• 12 Contrino J. et al. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996; 2: 209-215.
• 13 Milsom C. et al. The role of tumor-and host-related tissue factor pools in oncogene-driven tumor progression. Thromb Res 2007; 120S2: S82-91.
• 14 Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-745.
• 15 Noguchi M. et al. Correlation between antigenic and functional expression of tissue factor on the surface of cultured human endothelial cells following stimulation by lipopolysaccharide endotoxin. Thromb Res 1989; 55: 87-97.
• 16 Clauss M. et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172: 1535-1545.
• 17 Yu J. et al. Contribution of host-derived tissue factor to tumor neovascularization. Arterioscler Thromb Vasc Biol 2008; 28: 1975-1981.
• 18 Rauch U. et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000; 96: 170-175.
• 19 Scholz T. et al. Transfer of tissue factor from platelets to monocytes: role of platelet-derived microvesicles and CD62P. Thromb Haemost 2002; 88: 1033-1038.
• 20 Kawamoto T. et al. Tumor-derived microvesicles induce proangiogenic phenotype in endothelial cells via endocytosis. PLoS One 2012; 7: e34045
• 21 Dasgupta SK. et al. Developmental endothelial locus-1 (Del-1) mediates clearance of platelet microparticles by the endothelium. Circulation 2012; 125: 1664-1672.
• 22 Collier ME, Ettelaie C. Induction of endothelial cell proliferation by recombinant and microparticle-tissue factor involves beta1-integrin and extracellular signal regulated kinase activation. Arterioscler Thromb Vasc Biol 2010; 30: 1810-1817.
• 23 Collier ME, Ettelaie C. Regulation of the incorporation of tissue factor into microparticles by serine phosphorylation of the cytoplasmic domain of tissue factor. J Biol Chem 2011; 286: 11977-11984.
• 24 Ettelaie C. et al. Tissue factor-containing microparticles released from mesangial cells in response to high glucose and AGE induce tube formation in microvascular cells. Microvasc Res 2008; 76: 152-160.
• 25 Ettelaie C. et al. Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-κB. Biochim Biophys Acta Mol Basis Dis 2011; 1812: 1591-1600.
• 26 Osterud B, Bjorklid E. Tissue factor in blood cells and endothelial cells. Front Biosci (Elite Ed) 2012; 4: 289-299.
• 27 Zachowski A. Phospholipids in animal eukaryotic membranes: transverse asymmetry and movement. Biochem J 1993; 294: 1-14.
• 28 Hansen CB. et al. Tissue factor-mediated endocytosis, recycling, and degradation of factor VIIa by a clathrin-independent mechanism not requiring the cytoplasmic domain of tissue factor. Blood 2001; 97: 1712-1720.
• 29 Hamik A. et al. Down-regulation of monocyte tissue factor mediated by tissue factor pathway inhibitor and the low density lipoprotein receptor-related protein. J Biol Chem 1999; 274: 4962-4969.
• 30 Zerial M, McBride H. Rab proteins as membrane organizers. Nat Rev Mol Cell Biol 2001; 2: 107-117.
• 31 van der Sluijs P. et al. The small GTP-binding protein rab4 controls an early sorting event on the endocytic pathway. Cell 1992; 70: 729-740.
• 32 van der Bliek AM. A sixth sense for Rab5. Nat Cell Biol 2005; 7: 548-550.
• 33 Haas AK. et al. A GTPase-activating protein controls Rab5 function in endocytic trafficking. Nat Cell Biol 2005; 7: 887-893.
• 34 Ullrich O. et al. Rab11 regulates recycling through the pericentriolar recycling endosome. J Cell Biol 1996; 135: 913-924.
• 35 Chen W. et al. Rab11 is required for trans-Golgi network-to-plasma membrane transport and a preferential target for GDP dissociation inhibitor. Mol Biol Cell 1998; 9: 3241-3257.
• 36 Díaz E. et al. A novel Rab9 effector required for endosome-to-TGN transport. J Cell Biol 1997; 138: 283-290.
• 37 Barbero P. et al. Visualization of Rab9-mediated vesicle transport from endosomes to the trans-Golgi in living cells. J Cell Biol 2002; 156: 511-518.
• 38 Mandal SK. et al. Tissue factor trafficking in fibroblasts: involvement of protease-activated receptor-mediated cell signaling. Blood 2007; 110: 161-170.
• 39 Feng Y. et al. Rab 7: an important regulator of late endocytic membrane traffic. J Cell Biol 1995; 131: 1435-1452.
• 40 Méresse S. et al. The rab7 GTPase resides on a vesicular compartment connected to lysosomes. J Cell Sci 1995; 108: 3349-3358.
• 41 Ceresa BP, Bahr SJ. Rab7 activity affects epidermal growth factor:epidermal growth factor receptor degradation by regulating endocytic trafficking from the late endosome. J Biol Chem 2006; 281: 1099-1106.
• 42 Shet AS. et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003; 102: 26780-2683.
• 43 Aras O. et al. Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood 2004; 103: 4545-4553.
• 44 Piccin A. et al. Circulating microparticles: pathophysiology and clinical implications. Blood Rev 2007; 21: 157-171.
• 45 Dean WL. et al. Proteomic and functional characterisation of platelet microparticle size classes. Thromb Haemost 2009; 102: 711-718.
• 46 Diamant M. et al. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002; 106: 2442-2447.
• 47 Aharon A. et al. Monocyte-derived microparticle and exosomes induce procoagulant and apoptotic effects on endothelial cells. Thromb Haemost 2008; 100: 878-885.
• 48 Angelillo-Scherrer A. Leukocyte-derived microparticles in vascular homeostasis. Circ Res 2012; 110: 356-369.